Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|April 12, 2017
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasoneVéronique Leblond, Pierre Morel, Marie-Sarah Dilhuidy, et al.
Bone Marrow Transplantation|February 12, 2022
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective studyDomitille Costes-Tertrais, Thomas Hueso, Thomas Gastinne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemiaTadeusz Robak, Anna Dmoszynska, Philippe Solal-Céligny, et al.
Eclinicalmedicine|August 21, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyPier Luigi Zinzani, Marek Trněný, Vincent Ribrag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphomaVéronique Leblond, Steve Johnson, Sylvie Chevret, et al.
Leukemia Research|December 20, 2014
Azacitidine for the treatment of relapsed and refractory AML in older patientsRaphael Itzykson, Sylvain Thépot, Céline Berthon, et al.
British Journal of Haematology|July 1, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patientsPhilippe Rousselot, Luigina Mollica, Joëlle Guilhot, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Pageof 5